Originally December 2021. Maintained for archival reference; current SARS-CoV-2 variants continue to be addressed by the same conserved-region primer design.
Pro-Lab Diagnostics ran in-silico alignment of every named SARS-CoV-2 variant (Alpha, Beta, Gamma, Delta, Omicron BA.1) against the primer-binding regions of the Optigene Genie® LAMP COVID-19 assay and the Pro-Amp HT RT-PCR assay. Because the assays anchor in conserved viral targets — and because LAMP uses 4-6 primers per reaction — no primer redesign was required. Wet-lab runs against Omicron BA.1 patient material confirmed detection "without issue."
Key Facts
- Variants validated (Dec 2021): Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Omicron BA.1.
- Method: In-silico alignment of variant consensus genomes against primer-binding sites + wet-lab confirmation on patient and synthetic controls.
- Platforms tested: Optigene Genie® II/III/HT (LAMP) and Pro-Amp HT / Bio-Rad CFX (RT-PCR).
- Design principle: Primers anchored in conserved genomic regions, not the variable spike (S) gene.
- LAMP redundancy: 4-6 primers per reaction (F3, B3, FIP, BIP, LoopF, LoopB) — single-base mismatches rarely abolish amplification.
- Outcome: No primer redesign required for any variant from Alpha through Omicron BA.1.
What changed with Omicron
When the World Health Organization designated B.1.1.529 a Variant of Concern on 26 November 2021 and named it Omicron, the laboratory community had a legitimate concern: this variant carried more than 30 mutations in the spike (S) protein alone — far more than Alpha, Beta, Gamma, or Delta. Several spike-targeting commercial assays in Europe and South Africa reported "S gene target failure" (SGTF) within days, a useful screening proxy but also a warning sign that single-target chemistries can be undone by a sufficiently mutated genome.
The question for any laboratory running molecular SARS-CoV-2 testing was therefore not philosophical but operational: does my assay still amplify this variant, and how do I know?
The in-silico validation approach
Pro-Lab Diagnostics' approach to each new variant has been the same since 2020. Within 24-48 hours of a WHO designation, the molecular team pulls the consensus genome (and several individual GISAID submissions) for the variant and aligns it against every primer- and probe-binding region used in the company's molecular menu. The alignment is performed with standard pairwise tools and verified by a second analyst.
For Omicron BA.1, the alignment showed zero mismatches across the Optigene Genie® LAMP primer set and zero mismatches in the conserved N-gene region targeted by the Pro-Amp HT RT-PCR assay. This is by design — the targets were chosen in early 2020 specifically because they sit in regions of the SARS-CoV-2 genome that are evolutionarily constrained. Mutations there tend to be lethal for the virus, so they don't accumulate in circulating populations.
Wet-lab confirmation followed within the same week. Charles Grice III, Pro-Lab's Technical Supervisor, ran the validation panel on both Pro-Amp HT and Bio-Rad CFX instruments using a combination of synthetic Omicron BA.1 RNA controls and clinical positive samples sequence-confirmed as BA.1 by an external reference lab. His summary at the time: "our findings in the detection of the Omicron variant have gone without issue."
biotech Variant-Robust LAMP Platform Optigene Genie® LAMP COVID-19 — primer set validated against all known SARS-CoV-2 variants Isothermal RT-LAMP, ~30-minute result, runs on Genie II / III / HT. Conserved-region primers; no redesign required from Alpha through current Omicron sub-lineages. arrow_forwardWhy LAMP is structurally mutation-tolerant
Reverse-transcription LAMP (RT-LAMP) uses between four and six primers per reaction: the outer F3 and B3 primers, the inner FIP and BIP primers (each itself a fused two-region oligo, so functionally four binding domains), and the optional Loop-F and Loop-B accelerators. All of these must hybridize to a contiguous ~250-base stretch of the target for amplification to initiate and accelerate.
This architecture is what makes LAMP unusually robust to point mutations. A single mismatch beneath a TaqMan probe in a single-probe RT-PCR can collapse fluorescence; the same mismatch beneath one of six LAMP binding domains usually does not, because the remaining five domains are intact and the cooperative strand-displacement reaction proceeds. The variant has to mutate multiple primer-binding sites simultaneously to escape — and conserved-region targets are, by definition, the regions where that is least likely to happen.
Variant-by-variant summary
| WHO label | Pango lineage | First seen | Pro-Lab assay status (Dec 2021) |
|---|---|---|---|
| Alpha | B.1.1.7 | Sep 2020 (UK) | Detected; 0 mismatches |
| Beta | B.1.351 | Oct 2020 (ZA) | Detected; 0 mismatches |
| Gamma | P.1 | Nov 2020 (BR/JP) | Detected; 0 mismatches |
| Delta | B.1.617.2 | Oct 2020 (IN) | Detected; 0 mismatches |
| Omicron | BA.1 | Nov 2021 (ZA/BW) | Detected; 0 mismatches, wet-lab confirmed |
Sample-to-result workflow
The validated assay does not exist in isolation. Pro-Lab's recommended workflow pairs the Optigene Genie® LAMP chemistry with one of two extraction options — the Pro-Mag magnetic-bead kit for automated 32- or 96-sample batches, or the Pro-Spin silica-column kit for smaller manual runs. Both extractions feed either the LAMP or the RT-PCR readout, and both have been validated against the same variant panel.
Forward-looking note (2026)
In the four years since this article was originally published, multiple Omicron sub-lineages (BA.2, BA.4/5, BQ.1, XBB, EG.5, JN.1, KP.3) have emerged. Pro-Lab has repeated the in-silico alignment exercise for each WHO-designated variant. To date, no primer redesign has been required, and the conserved-region rationale described above continues to hold. Laboratories using the Optigene Genie® LAMP COVID-19 assay can therefore treat the variant-tracking question as solved-by-design rather than as a per-variant validation burden.
Frequently Asked Questions
How did Pro-Lab Diagnostics validate detection of the Omicron variant?
Pro-Lab used an in-silico approach, aligning each variant's published consensus genome (Alpha, Beta, Gamma, Delta, Omicron BA.1) against the primer-binding regions used in the Optigene Genie® LAMP assay and the Pro-Amp HT RT-PCR assay. Wet-lab confirmation against patient samples and synthetic variant controls produced no detection failures.
Why doesn't Omicron escape Pro-Lab's LAMP and PCR assays?
The assays target conserved regions of the SARS-CoV-2 genome — sequences that have remained essentially unchanged across all variants because mutations there would disrupt essential viral function. Omicron's defining mutations cluster in the spike (S) gene, while Pro-Lab's primers anchor in conserved targets outside that region.
Why does LAMP offer better mutation tolerance than single-target PCR?
LAMP uses 4-6 primers (F3, B3, FIP, BIP, and optional LoopF/LoopB) that all must bind a contiguous stretch of target. This built-in redundancy means a single-base mismatch under one primer rarely abolishes amplification — there are still 3-5 other primers driving the reaction. Single-probe PCR can be knocked out by one mismatch under the probe; LAMP usually is not.
Will the Optigene Genie® LAMP assay detect newer variants beyond Omicron BA.1?
Yes. The same conserved-region primer-design principle that protects against Alpha through Omicron BA.1 continues to protect against subsequent Omicron sub-lineages (BA.2, BA.4/5, XBB, JN.1, and later). Pro-Lab repeats in-silico alignment whenever a WHO-named variant emerges and has not required a redesign to date.
What instruments run the validated assay?
The LAMP COVID-19 assay runs on Optigene Genie® II, Genie III, or Genie HT isothermal fluorometers (results in approximately 30 minutes). The companion RT-PCR validation was performed on Pro-Amp HT and Bio-Rad CFX platforms. Both extraction workflows — Pro-Mag magnetic-bead and Pro-Spin silica column — feed either chemistry.
For technical details on the Optigene Genie® LAMP COVID-19 assay or to discuss variant-surveillance workflows, contact info@pro-lab.us or visit the Optigene Genie® product page.